Developer of oncology drugs intended to deliver breakthroughs that drive innovation and transform cancer treatment. The company's drug is a potent PARP inhibitor that prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells, helping cancer patients by targeting multiple solid tumors as monotherapy and for combination with other anti-cancer agents.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Early Stage VC (Series B) | 01-Oct-2020 | $33.9M | 000.00 | Completed | Clinical Trials - Phase 1 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Kiwoom Securities Company | Corporation | Minority | 000 0000 | 000000 0 | |
Mirae Asset Capital | Other | Minority | 000 0000 | 000000 0 | |
Seoul Investment Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
TS Investment | Other | Minority | 000 0000 | 000000 0 | |
Yuanta Investment | Venture Capital | Minority | 000 0000 | 000000 0 |